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Introduction
Diseases of the adrenal gland are as important for the general prac-
titioner as for the endocrine specialist. The high prevalence of some 
adrenal endocrinopathies, such as adrenal incidentalomas (1–2 % 
of the population) and primary aldosteronism (6 % of hyperten-
sives), which affect millions of patients, makes adrenal diseases a 
relevant health issue. The high morbidity and mortality of some of 
the rarer adrenal diseases, i. e., Addison’s disease and Cushing’s 
syndrome (▶Table 1), make early detection and appropriate treat-
ment such a challenge for the health care system.
Progress in genomics, transcriptomics and steroidobolomics 
has advanced our understanding of adrenal pathologies including 
primary aldosteronism [1], Cushing’s syndrome [2], adrenocorti-
cal carcinoma [3], and pheochromocytoma [4]. Recent progress 
has been made in the pathophysiology of many rare adrenal dis-
eases. Foremost has been the identification of somatic driver mu-
tations in adrenal cortical neoplasms responsible for the character-
istic endocrine autonomy and limited proliferative activity of these 
endocrine tumors [1]. The rich genetic background of neoplasms 
derived from adrenal and extra-adrenal chromaffin cells is well es-
tablished with over 16 germline mutation identified to date, many 
of these and other (HIF2a, IDH1 & 2, HRAS) also contributing via 
somatic driver events [4]. It is within this horizon that adrenal dis-
eases have become a general topic in research and in clinics.
The Adrenal Cortex Conference in Munich 2018
In June 2018, we had the privilege to organize the 18th Adrenal Cor-
tex Conference in Munich. Since 1984 the Conference on the 
 Adrenal Cortex has provided an exciting combination of science 
and resources for basic and clinical scientists. The 2018 conference 
continued the tradition of including renowned speakers covering 
the latest research on adrenal development, hormone signaling, 
steroidogenesis, adrenal insufficiency, primary aldosteronism, 
Cushing’s syndrome and adrenal cancer. As in previous meetings, 
the Keith L. Parker Memorial Lecture was awarded to an interna-
tional leader for his contribution to adrenal research. This year’s 
laureate was William E. Rainey, the Jerome W. Conn Professor at the 
University of Michigan, Ann Arbor, USA, who presented a lecture 
on his most recent research on the molecular pathophysiology of 
primary aldosteronism. Two hundred scientists from around the 
globe participated in this prime event of adrenal research giving 
the meeting a truly international flavor. More than 100 investiga-
tors including many students and young post-docs presented their 
research as posters or oral communications.
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We acknowledge the generous support of the Deutsche 
Forschungsgemeinschaft, which enabled us to invite many of the 
internationally leading researchers in the field. Furthermore, the 
present March volume of Experimental and Clinical Endocrinology 
and Diabetes is entirely dedicated to reviews covering advances in 
the field of primary aldosteronism. They are written by experts in 
their respective fields and include twelve invited articles summa-
rizing main topics covered at the symposium.
Primary aldosteronism (PA) has been identified as the leading 
endocrine cause of hypertension in recent years. Although still 
 utterly underdiagnosed in clinical practice recent data point to a 
higher detection rate in some countries. PA is easily picked up if 
screened by the aldosterone-to-renin ratio. However, there are 
many factors influencing sensitivity and specificity of the ratio, an 
area explored by the review of Schilbach, et al. [5]. Perez-Rivas 
et al. [6] cover in their review on familial hyperaldosteronism the 
most recent genetic findings currently leading to a potential reclas-
sification. Although there has been a debate about the true preva-
lence, with estimates up to 6 % in systematic screening approaches 
[7], genetically confirmed familial hyperaldosteronism remains a 
quite rare entity affecting less than 1 % of diagnosed cases of pri-
mary aldosteronism. Usually, affected patients present early in in-
fancy and have a severe course of the disease. Yang et al. [8] pro-
vide an analysis of the outcome of adrenalectomy in unilateral pri-
mary aldosteronism. Based on a recently established expert 
consensus of 31 specialists, assessment of outcome has been 
standardized allowing improved comparison between cohorts of 
different geographic and genetic backgrounds [9]. However, this 
analysis also demonstrated that a certain percentage of patients 
have in biochemical terms persistent hyperaldosteronism, and the 
underlying pathophysiology is discussed in this review.
Two manuscripts review the recent advances in the treatment 
of malignant adrenal diseases, namely adrenocortical carcinoma 
(ACC) and malignant pheochromocytoma/paraganglioma (PPGL). 
A major breakthrough in treatment of adrenocortical carcinoma 
has been the FIRMACT trial published in 2012 [10] which reported 
results of a randomized trial comparing 2 chemotherapeutic regi-
mens in stage IV ACC. As a result of this trial, multiple second and 
third line therapies have been evaluated [11] which are reported in 
the review article by Megerle et al. [12]. Approximately 10 % of all 
PPGL are malignant, and treatment options in metastasized disease 
stages include radioactive treatment options (MIBG, somatostatin 
receptor based approaches), classical chemotherapy protocols and 
targeted treatment approaches. Nölting et al. [13] provide a com-
prehensive overview of the most recent advances in the field, in-
cluding promising pre-clinical data not yet used in clinical practice.
Erlic and Beuschlein [14] summarize the metabolic alterations 
found in PPGL, including impaired glucose homeostasis and lipoly-
sis activation, changes in body weight, fat mass and distribution. 
Schreiner et al. cover the highly relevant topic of perioperative man-
agement of adrenal tumors [15]. In clinical practice this area is as-
sociated with serious morbidity and mortality which can be avoid-
ed by appropriate management.
Cushing disease (CD), caused by corticotroph adenomas of the 
pituitary, is a rare devastating disease with high clinical burden. Re-
mission by transsphenoidal adenomectomy is achieved in 78 % [16], 
but often metabolic, cardiovascular, musculoskeletal and psychiat-
ric comorbidities persist after long-term biochemical control. These 
chronically ill patients show an increased mortality despite disease 
remission. According to the review by Stalla et al. [17], comorbidi-
ties should be treated aggressively and life-long surveillance is nec-
essary to identify tumor recurrence at an early stage. Kamilaris et al. 
[18] give an excellent overview of genetics and clinics of primary pig-
mented nodular adrenal disease, a rare cause of adrenal Cushing’s 
syndrome, often associated with additional syndromatic features.
This special issue also highlights the importance of non-tumorous 
adrenal diseases with high morbidity, such as Addison’s disease and con-
genital adrenal hyperplasia. In a timely review, Barthel et al. [19] reflect 
upon current treatment standards in Addison’s disease and improve-
ments in long-term care. Reisch [20] summarizes the long-term seque-
lae observed in patients with congenital adrenal hyperplasia. There is a 
shift from the pediatric focus on management of adrenal crisis and 
growth to adult problems, namely reproduction and prevention of long-
term cardiovascular and metabolic consequences of the disease.
▶Table 1 Incidence and prevalence of adrenal diseases in Europe.
Annual incidence Prevalence Morbidity Mortality
Congenital adrenal 
hyperplasia
1:10.000–1:15.000 5.8 crises per 100
patient-years;
salt wasting:
8.8; simple
virilising: 2.5
The HR of dying 2.3 (95 % CI, 1.2–4.3) in CAH males 
and 3.5 (95 % CI, 2.0–6.0) in CAH females compared 
with controls
Addison’s disease 4.5/1000.000 82–144/ 1000.000 6–8 adrenal crisis/ 100 
patients/year
0.5 deaths/100 patient-years from adrenal crisis
Primary  
aldosteronism
n.k. 4–6 % of hypertensive 
population
OR for stroke: 4.2; OR 
for MI: 6.5; 
OR for AF: 12.1 
compared to EH
2 times increased for treated PA (IAH)
Cushing disease 1–3/1000.000 66/1000.000 SMR for all-cause mortality in treated CD: 1.61
Incidentally detected 
adrenal mass
n.k. 1–2 % of general 
population
n.k. n.k.
Adrenocortical 
carcinoma
0.7–2.0/ 1.000.000 Median survival: 3–4 years, 5-year survival 60–80 % for 
localized tumors, and 10–20 % for metastatic disease
N.k., not known; OR, Odds ratio; EH; essential hypertension; PA, primary aldosteronism; IAH, idiopathic adrenal hyperplasia; CD, Cushing disease; SMR, 
standard mortality rate; AF, atrial fibrillation: MI, myocardial infarction; HR, hazard ratio
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The final manuscript by Di Dalmazi [21] addresses recent pro-
gress in adrenal incidentalomas, a topic which has been covered by 
a European guideline in 2016 [3]. In clinical practice these guide-
lines have proven to be very helpful. However, as in other areas of 
adrenal research, many open questions remain and have to be ad-
dressed by future studies.
It is within this context that the recently established clinical re-
search center (CRC), “The adrenal gland: central relay in health and 
disease” [22], is well suited to approach clinical issues and basic re-
search questions. The Deutsche Forschungsgemeinschaft approved 
funding for this program with 13 mio € from 2017 to 2021, with the 
option of a further extension until 2029. The 17 research projects and 
two central support projects at the University Hospitals of Dresden, 
Munich and Würzburg cover a broad spectrum ranging from sepsis 
research to Cushing’s syndrome, and adrenal gland organ replacement 
to rodent models of autoimmune adrenal disease. Several of its prin-
cipal investigators of the CRC are authors of reviews of this special 
issue. Other authors are close collaborators of the CRC scientists, re-
flecting its international outreach. This special issue of Experimental 
and Clinical Endocrinology and Diabetes provides the interested read-
er with an opportunity to understand where we are, and where our 
research has to go until the next Adrenal Cortex Conference in 2020.
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